GlassScriptPhysician profile
Erica Gibson
NPI 1235522780
$10,633.49
in general payments reported to CMS, 2019-2025
39 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,021 · 2022: $2,348 · 2023: $2,357 · 2024: $2,338 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,443.69 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,293.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,194.34 | 2021-2025 | |
| Lilly USA, LLC | $1,184.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,043.82 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $789.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.39 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $514.73 | 2021-2025 | |
| Astellas Pharma US INC | $352.27 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $324.90 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $214.54 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $180.75 | 2021-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.03 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $124.81 | 2024-2025 | Voquezna |
| Sunovion Pharmaceuticals INC. | $100.46 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $98.94 | 2021-2022 | |
| Antares Pharma, INC. | $84.90 | 2022-2025 | Xyosted |
| Exact Sciences Corporation | $82.62 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $72.20 | 2021 | |
| Amarin Pharma, INC. | $70.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.80 | 2021-2022 | |
| Mylan Specialty L.P. | $69.49 | 2021-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $60.82 | 2022-2023 | Quviviq |
| Grifols USA, LLC | $51.43 | 2024 | Prolastin-C Liquid |
| Sanofi Pasteur INC. | $46.06 | 2021-2023 | |
| Esperion Therapeutics, INC. | $41.59 | 2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.78 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $40.29 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.07 | 2021-2022 | |
| Lundbeck LLC | $28.60 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $27.37 | 2023-2024 | Onzetra Xsail, Contrave |
| Bausch Health US, LLC | $24.86 | 2021 | |
| Dexcom, INC. | $20.16 | 2024 | Dexcom G6 Transmitter |
| Bardy Diagnostics, INC. | $20.00 | 2021 | |
| Silk Road Medical, INC. | $18.23 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Nestle Healthcare Nutrition INC. | $17.09 | 2021 | |
| Sumitomo Pharma America, INC. | $14.71 | 2023 | Gemtesa |
| Nevro Corp. | $14.01 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.